|
September 5. FDA posts quarterly report of potential safety issues. FDA News
September 4. FDA announces that manufacturers of TNF-blocker drugs (Cimzia, Enbrel, Humira, and Remicade) must highlight the risk of fungal and serious opportunistic infections. Drug Information; FDA News
August 25. FDA updates the Information for Healthcare Professionals sheet for Tysabri (natalizumab). Drug Information
August 21. FDA issues an Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia). Drug Information
August 18. FDA updates the Information for Healthcare Professionals sheet for Byetta (exenatide). Drug Information
More "What's New" |
